Avacta appoints new members to Scientific Advisory Board of Therapeutics Division
Avacta Group, a clinical stage biopharmaceutical company developing cancer therapies and diagnostics based on its proprietary Affimer and pre|CISION platforms, has made new appointments to its Scientific Advisory Board (SAB),reflecting the progress ofthe Therapeutics Division and Avacta’s transition to a clinical stage company.
